No Prescription |
 |
 | ||
|
Trifeme Lybrel |
|
| ||
No Prescription » Prescription Drugs 16 » Trifeme Lybrel TRIFEME is indicated for the prevention of pregnancy.Each TRIFEME package contains 28 tablets; 6 brown tablets each containing 30 microgram ethinyloestradiol and 50 microgram levonorgestrel followed by 5 white tablets each containing 40 microgram of ethinyloestradiol and 75 microgram levonorgestrel followed by 10 yellow tablets each containing 30 microgram ethinyloestradiol and 125 microgram levonorgestrel followed by 7 red inert tablets.DOSAGE AND ADMINISTRATIONHow to Take TRIFEMETo achieve maximum contraceptive effectiveness TRIFEME must be taken in the order directed on the package and at intervals not exceeding 24 hours. Patients should be instructed to take the tablets at about the same time every day preferably after the evening meal or at bedtime. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started on the day after the current pack is completed. A withdrawal bleed usually starts on day 2-3 after the last active tablet and may not have finished before the next pack is started. Buy Trifeme Lybrel and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Trifeme Lybrel: Product Type: Prescription Drugs 16 Trifeme ( Lybrel Seasonale Generic Ethinyloestradiol/Levonorgestrel ) Trifeme (Lybrel Seasonale Generic Ethinyloestradiol/Levonorgestrel) Lybrel Seasonale Generic Ethinyloestradiol/Levonorgestrel Refer Pack Lybrel Seasonale Generic Ethinyloestradiol/Levonorgestrel Trifeme
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
